enGene Holdings Inc.
enGene Holdings Inc. (ENGN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ENGN · as of Sep 30, 2025
Ownership Breakdown
38
Institutional Holders
▲ 1 vs Q2
$279.13M
Total Inst. Value
▲ $132.00M vs Q2
51.19M
Shares Outstanding
freeFloat 42.03%
40.87M
13F Shares Held
▲ 448,012 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ENGN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FCPM III SERVICES B.V. biological products, (no diagnostic substances) | 9.63M | 18.85% | 18.85% | $65.79B | Nov 14, 2025 | — held |
VR ADVISER, LLC biological products, (no diagnostic substances) | 5.05M | 9.88% | 9.88% | $34.47B | Nov 14, 2025 | — held |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 4.99M | 9.77% | 9.77% | $34.11B | Nov 14, 2025 | — held |
BLUE OWL CAPITAL HOLDINGS LP biological products, (no diagnostic substances) | 3.28M | 6.42% | 6.42% | $22.39B | Nov 12, 2025 | ▼ 450.0K |
CORMORANT ASSET MANAGEMENT, LP biological products, (no diagnostic substances) | 2.32M | 4.55% | 4.55% | $15.87B | Nov 14, 2025 | — held |
BRAIDWELL LP biological products, (no diagnostic substances) | 2.27M | 4.44% | 4.44% | $15.48B | Nov 14, 2025 | NEW |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 2.24M | 4.38% | 4.38% | $15.29B | Nov 14, 2025 | ▼ 2.32M |
PERCEPTIVE ADVISORS LLC biological products, (no diagnostic substances) | 2.10M | 4.10% | 4.10% | $14.32B | Nov 14, 2025 | NEW |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.21M | 2.36% | 2.36% | $8.25B | Nov 14, 2025 | ▲ 100 |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.16M | 2.27% | 2.27% | $7.90B | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+148.1K shares7
New Positions
first time holders8
Decreased
−5.04M shares6
Sold Out
fully exitedNet shares change (top 50)
4.89M
+148.1K / −5.04M
Net new holders
+0
7 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ENGN insider trading · insider activity
Source: SEC Form 4
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
CHEUNG ANTHONY TZEYEW Chief Scientific Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Giguere Lee Chief Legal Ofc. and Corp Secy | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Nichols Alexander Julian Chief Strategy & Ops. Ofc | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Daws D. Ryan Chief Financial Officer | Jan 30, 2026 | Award | 220,000 | $9.53 | $2.10M | 220.0K | Form 4 ↗ |
Cooper Ronald Harold Wilfred CEO & President | Jan 30, 2026 | Award | 801,000 | $9.53 | $7.63M | 801.0K | Form 4 ↗ |
Connolly Joan Chief Technology Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Boyd Matthew Ross Chief Regulatory Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Buck Jill Chief Development Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Sweiti Hussein Chief Medical Officer | Sep 30, 2025 | Award | 600,000 | $6.83 | $4.10M | 600.0K | Form 4 ↗ |
Boyd Matthew Ross Chief Regulatory Officer | Jul 8, 2025 | Award | 100,000 | $3.83 | $383.0K | 100.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
enGene Holdings Inc. (ENGN) is primarily owned by institutional investors, who hold approximately 79.8% of total shares outstanding. Company insiders own approximately 57.97%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of enGene Holdings Inc. is FCPM III SERVICES B.V., holding approximately 9.63 million shares — equal to 18.85% of outstanding shares — as of September 30, 2025.
A total of 38 institutional investors currently hold ENGN stock, with a combined institutional value of approximately $279,131,773 as of the most recent 13F filing period.
Frequently asked questions
ENGN ownershipenGene Holdings Inc. (ENGN) is primarily owned by institutional investors, who hold approximately 79.8% of shares. The largest shareholder is FCPM III SERVICES B.V. with a 18.85% stake. Company insiders hold 57.97%. Data sourced from SEC Form 13F as of September 30, 2025.